Form 4: Syntone Ventures LLC Acquires Shares and Warrants in Outlook Therapeutics Private Placement

Syntone Ventures LLC acquired 714,286 shares of common stock and warrants to purchase 1,071,429 shares of common stock in a private placement by Outlook Therapeutics, Inc. on April 15, 2024.

Summary

• Syntone Ventures LLC acquired shares and warrants of Outlook Therapeutics, Inc. through a private placement.
• The transaction occurred on April 15, 2024, as per the Securities Purchase Agreement dated January 22, 2024.
• Syntone purchased 714,286 shares of common stock and warrants to acquire 1,071,429 shares of common stock.
• The purchase price was $7.00 per share and accompanying warrant.
• Effective March 14, 2024, Outlook Therapeutics implemented a 1-for-20 reverse stock split.
• Prior to the split, Syntone held 19,823,045 shares, which became 991,152 shares after the split.
• Following the reported transaction, Syntone Ventures LLC beneficially owns 1,705,438 shares of common stock and warrants for 1,071,429 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects an investment by Syntone Ventures, indicating confidence in Outlook Therapeutics. However, the reverse stock split suggests previous challenges in maintaining share price.

Positives

• Syntone Ventures LLC has increased its investment in Outlook Therapeutics, demonstrating confidence in the company.
• The private placement provides Outlook Therapeutics with additional capital.

Industry Context

Private placements are a common method for companies, especially in the biotech sector, to raise capital. Syntone Ventures' investment suggests potential confidence in Outlook Therapeutics' future prospects, particularly concerning its ophthalmic treatments.

Stakeholder Impact

• Shareholders may see this as a positive sign, as it brings in additional capital.
• The capital injection could support the company's operations and development programs.

Key Dates